<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02230787</url>
  </required_header>
  <id_info>
    <org_study_id>186/13</org_study_id>
    <nct_id>NCT02230787</nct_id>
  </id_info>
  <brief_title>Gingival Recession Coverage With and Without Emdogain</brief_title>
  <official_title>Effect of Emdogain on Wound Healing After Gingival Recession Coverage Using Connective Tissue Graft: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Bern</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Bern</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Enamel matrix proteins have been shown to play a crucial role during tooth development and&#xD;
      its supporting tissues. This is used in periodontal surgery where regeneration of lost&#xD;
      tissues around the teeth is intended. Emdogain, a product of Straumann Institute contains&#xD;
      these matrix proteins and has been successfully used in regenerative periodontal surgery for&#xD;
      more than 16 years.&#xD;
&#xD;
      The treatment of gum recession is a common requirement, more and more patients are seeking&#xD;
      treatment at the investigators' clinic due to aesthetic concern, root sensitivity and&#xD;
      difficulties in performing adequate oral hygiene. The standard treatment comprises the&#xD;
      transplantation of a piece of connective tissue from the palate to the denuded root surface.&#xD;
      In many cases Emdogain is additionally applied to enhance healing. So far the effect of&#xD;
      Emdogain on the early wound healing process after surgical root coverage has not been&#xD;
      investigated.&#xD;
&#xD;
      The purpose of the investigators' study is to compare early wound healing parameters between&#xD;
      treatment with and without Emdogain. For this study 40 patients undergoing root coverage&#xD;
      surgery at the investigators' department will be included. Early wound healing features&#xD;
      between the two groups will be described and compared. Furthermore, inflammatory markers&#xD;
      typical for early healing will be evaluated together with patients'subjective postoperative&#xD;
      comfort. Finally, outcomes 6 months after the treatment will be assessed. The investigators'&#xD;
      hypothesis is that Emdogain treatment enhances wound healing and decreases post-operative&#xD;
      complication rates.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background&#xD;
&#xD;
      Effect of Emdogain on wound healing after gingival recession coverage using connective tissue&#xD;
      graft: a pilot study Emdogain Treatment Emdogain (Institute Straumann, Basel Switzerland) is&#xD;
      an enamel matrix protein derivative with the vehicle propylene glycol alginate. Emdogain has&#xD;
      been used for more than 16 years for regenerative periodontal treatment of intrabony, class&#xD;
      II furcation and recession defects. Animal and human histological studies have provided&#xD;
      evidence for periodontal regeneration (e.g. formation of root cementum, periodontal ligament&#xD;
      and alveolar bone) following the application of Emdogain in conjunction with periodontal&#xD;
      surgery. The use of Emdogain has been shown to significantly improve the clinical outcomes&#xD;
      evidenced by probing depth reduction, and clinical attachment gain and is considered today as&#xD;
      a routine procedure.&#xD;
&#xD;
      Background Therapy of buccal gingival recession is a common indication for treatment in order&#xD;
      to improve plaque control thus preventing gingivitis and root caries but also to improve&#xD;
      aesthetics and root sensitivity. The ultimate goal of a root coverage procedure is the&#xD;
      complete coverage of the root surface and, in the same time, to obtain a similar appearance&#xD;
      of the regenerated soft tissues to the surrounding intact tissues. The use of palatal&#xD;
      connective tissue graft in conjunction with a coronally advanced flap (CAF) is a well&#xD;
      established clinical procedure for the treatment of gingival recessions. Its use has been&#xD;
      shown to result in predictable root coverage, higher increase in keratinized tissue and more&#xD;
      stable long-term outcomes compared to the use of CAF and is considered today state of the&#xD;
      art. Furthermore, recent data also appear to indicate that the combination of Emdogain and&#xD;
      CTG may additionally improve the clinical outcomes. Therefore, the standard surgical&#xD;
      procedure for the treatment of gingival recessions at the Department of Periodontology&#xD;
      includes the use of connective tissue graft either with or without the use of Emdogain.&#xD;
&#xD;
      Interestingly, despite the fact that Emdogain is commonly used, no information on its effects&#xD;
      upon early wound healing is available.&#xD;
&#xD;
      Hence, the aim of this study is to evaluate the effect of Emdogain on early wound healing, as&#xD;
      assessed by means of clinical parameters and inflammatory markers following recession&#xD;
      coverage surgery.&#xD;
&#xD;
      Study population and methodology Patient groups compared: in the treatment group, patients&#xD;
      undergoing a recession coverage surgery will be treated with Emdogain whereas in the control&#xD;
      group, patients will not receive Emdogain. A total of 40 patients, 20 in each group will be&#xD;
      included.&#xD;
&#xD;
      Preoperative inflammatory markers will be assessed at the preoperative examination and two&#xD;
      days after surgery by dipping paper points into the crevicular fluid. Furthermore the&#xD;
      investigators will assess whether remnants of Emdogain are still traceable two days after&#xD;
      surgery. Wound healing after root coverage procedure is assessed using the &quot;early wound&#xD;
      healing index (EHI)&quot; defined by Wachtel et al. According to Wachtel et al., wound healing is&#xD;
      quantified and graded into 5 stages.&#xD;
&#xD;
      Additionally, the post-operative healing process will be judged by a patient questionnaire.&#xD;
      Finally root coverage is measured as the distance from the CEJ (Cemento Enamel Junction) to&#xD;
      the Margo Gingivae in mm.&#xD;
&#xD;
      Objective&#xD;
&#xD;
        1. To investigate the benefit of intraoperative use of Emdogain on early wound healing&#xD;
           during the first two weeks after gingival recession coverage. Early wound healing&#xD;
           parameters will be assessed at both the site of explantation of the tissue graft as well&#xD;
           as at the site of implantation.&#xD;
&#xD;
        2. To investigate the effect of Emdogain on inflammatory markers in crevicular fluid and&#xD;
           whether Emdogain is traceable after two days after application.&#xD;
&#xD;
        3. To investigate its influence on post-operative pain and interference with daily&#xD;
           activities during the first two weeks (patient's questionnaire).&#xD;
&#xD;
        4. The post-operative result will also be assessed after 6 months.&#xD;
&#xD;
      Methods&#xD;
&#xD;
      The present prospective study will include a total of 40 patients, 20 patients in each of the&#xD;
      2 groups (Emdogain group and control group). All procedures will be elective procedures.&#xD;
      After oral and written informed consent, the study will comprise the collection of crevicular&#xD;
      fluid sampling and clinical data as well as the filling of a patient questionnaire. The study&#xD;
      will be conducted as randomized prospective study. In the treatment group the procedure will&#xD;
      be performed with Emdogain, in the control group, root coverage will be performed without,&#xD;
      respectively. All procedures will be performed by one experienced operator. Patients will all&#xD;
      be treated with the standard surgical procedure of the University of Bern. In the patient&#xD;
      group with Emdogain, tissue graft and explantation site will be covered with Emdogain, in the&#xD;
      patient group without Emdogain, no Emdogain will be used. After inclusion of the patients,&#xD;
      the study duration will last 6 months for each patient.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2014</start_date>
  <completion_date type="Actual">February 14, 2017</completion_date>
  <primary_completion_date type="Actual">April 22, 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in wound healing</measure>
    <time_frame>2, 7 and 14 days after surgery</time_frame>
    <description>Progress in wound healing assessed by the &quot;early wound healing index (EHI)&quot; previously defined by Wachtel et al.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Levels of post-procedural inflammatory markers</measure>
    <time_frame>2 and 7 days after surgery</time_frame>
    <description>Including IL- 8, IL-10, IL-1beta, MMP-8 and TGF beta-1, traceability of Emdogain in the operation field</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of patients' post-operative comfort</measure>
    <time_frame>2 days to 2 weeks after surgery</time_frame>
    <description>Assessed by patient questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Root coverage</measure>
    <time_frame>6 months after surgery</time_frame>
    <description>Measured in mm</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Gingival Recession</condition>
  <condition>Emdogain</condition>
  <arm_group>
    <arm_group_label>Recession coverage without Emdogain</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Recession coverage with Emdogain</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Recession coverage without Emdogain</intervention_name>
    <description>In the control group subjects the recession coverage surgery will be performed without Emdogain.</description>
    <arm_group_label>Recession coverage without Emdogain</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Recession coverage with Emdogain</intervention_name>
    <description>In the test group subjects the recession coverage surgery will be performed with Emdogain.</description>
    <arm_group_label>Recession coverage with Emdogain</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Gingival recession Miller class I and II&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Patients with a history of a chronic infectious or inflammatory diseases (i.e.&#xD;
             rheumatoid arthritis, systemic lupus erythematodes, Crohn's disease, or HIV-,&#xD;
             HCV-infection etc.&#xD;
&#xD;
          -  Patients with any clinical signs of an acute infection&#xD;
&#xD;
          -  Patients with renal failure (GFR &lt; 30ml/min)&#xD;
&#xD;
          -  Smoking &gt; 5 cigarettes per day&#xD;
&#xD;
          -  Patients &lt; 18 years of age&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anton Sculean, Prof. Dr. med. dent.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Periodontology, University of Bern</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Periodontology, University of Bern</name>
      <address>
        <city>Berne</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Grandin HM, Gemperli AC, Dard M. Enamel matrix derivative: a review of cellular effects in vitro and a model of molecular arrangement and functioning. Tissue Eng Part B Rev. 2012 Jun;18(3):181-202. doi: 10.1089/ten.TEB.2011.0365. Epub 2011 Dec 28.</citation>
    <PMID>22070552</PMID>
  </reference>
  <reference>
    <citation>Spahr A, Haegewald S, Tsoulfidou F, Rompola E, Heijl L, Bernimoulin JP, Ring C, Sander S, Haller B. Coverage of Miller class I and II recession defects using enamel matrix proteins versus coronally advanced flap technique: a 2-year report. J Periodontol. 2005 Nov;76(11):1871-80. doi: 10.1902/jop.2005.76.11.1871.</citation>
    <PMID>16274306</PMID>
  </reference>
  <reference>
    <citation>Wachtel H, Schenk G, Bohm S, Weng D, Zuhr O, Hurzeler MB. Microsurgical access flap and enamel matrix derivative for the treatment of periodontal intrabony defects: a controlled clinical study. J Clin Periodontol. 2003 Jun;30(6):496-504. doi: 10.1034/j.1600-051x.2003.00013.x.</citation>
    <PMID>12795787</PMID>
  </reference>
  <reference>
    <citation>Cairo F, Pagliaro U, Nieri M. Treatment of gingival recession with coronally advanced flap procedures: a systematic review. J Clin Periodontol. 2008 Sep;35(8 Suppl):136-62. doi: 10.1111/j.1600-051X.2008.01267.x.</citation>
    <PMID>18724847</PMID>
  </reference>
  <results_reference>
    <citation>Henriques PS, Pelegrine AA, Nogueira AA, Borghi MM. Application of subepithelial connective tissue graft with or without enamel matrix derivative for root coverage: a split-mouth randomized study. J Oral Sci. 2010 Sep;52(3):463-71. doi: 10.2334/josnusd.52.463.</citation>
    <PMID>20881341</PMID>
  </results_reference>
  <results_reference>
    <citation>Cueva MA, Boltchi FE, Hallmon WW, Nunn ME, Rivera-Hidalgo F, Rees T. A comparative study of coronally advanced flaps with and without the addition of enamel matrix derivative in the treatment of marginal tissue recession. J Periodontol. 2004 Jul;75(7):949-56. doi: 10.1902/jop.2004.75.7.949.</citation>
    <PMID>15341352</PMID>
  </results_reference>
  <results_reference>
    <citation>Aroca S, Molnar B, Windisch P, Gera I, Salvi GE, Nikolidakis D, Sculean A. Treatment of multiple adjacent Miller class I and II gingival recessions with a Modified Coronally Advanced Tunnel (MCAT) technique and a collagen matrix or palatal connective tissue graft: a randomized, controlled clinical trial. J Clin Periodontol. 2013 Jul;40(7):713-20. doi: 10.1111/jcpe.12112. Epub 2013 Apr 30.</citation>
    <PMID>23627374</PMID>
  </results_reference>
  <results_reference>
    <citation>Rasperini G, Roccuzzo M, Francetti L, Acunzo R, Consonni D, Silvestri M. Subepithelial connective tissue graft for treatment of gingival recessions with and without enamel matrix derivative: a multicenter, randomized controlled clinical trial. Int J Periodontics Restorative Dent. 2011 Apr;31(2):133-9.</citation>
    <PMID>21491012</PMID>
  </results_reference>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>August 12, 2014</study_first_submitted>
  <study_first_submitted_qc>September 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2014</study_first_posted>
  <last_update_submitted>April 19, 2017</last_update_submitted>
  <last_update_submitted_qc>April 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pilot study</keyword>
  <keyword>randomized clinical trial</keyword>
  <keyword>periodontal disease</keyword>
  <keyword>gingival recession</keyword>
  <keyword>Emdogain</keyword>
  <keyword>connective tissue</keyword>
  <keyword>wound healing</keyword>
  <keyword>inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gingival Recession</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02230787
org study id: 186/13
nct id: NCT02230787
lead sponsor: 
has dmc: No
Enamel matrix proteins have been shown to play a crucial role during tooth development and
      its supporting tissues. This is used in periodontal surgery where regeneration of lost
      tissues around the teeth is intended. Emdogain, a product of Straumann Institute contains
      these matrix proteins and has been successfully used in regenerative periodontal surgery for
      more than 16 years.

      The treatment of gum recession is a common requirement, more and more patients are seeking
      treatment at the investigators' clinic due to aesthetic concern, root sensitivity and
      difficulties in performing adequate oral hygiene. The standard treatment comprises the
      transplantation of a piece of connective tissue from the palate to the denuded root surface.
      In many cases Emdogain is additionally applied to enhance healing. So far the effect of
      Emdogain on the early wound healing process after surgical root coverage has not been
      investigated.

      The purpose of the investigators' study is to compare early wound healing parameters between
      treatment with and without Emdogain. For this study 40 patients undergoing root coverage
      surgery at the investigators' department will be included. Early wound healing features
      between the two groups will be described and compared. Furthermore, inflammatory markers
      typical for early healing will be evaluated together with patients'subjective postoperative
      comfort. Finally, outcomes 6 months after the treatment will be assessed. The investigators'
      hypothesis is that Emdogain treatment enhances wound healing and decreases post-operative
      complication rates.
Background

      Effect of Emdogain on wound healing after gingival recession coverage using connective tissue
      graft: a pilot study Emdogain Treatment Emdogain (Institute Straumann, Basel Switzerland) is
      an enamel matrix protein derivative with the vehicle propylene glycol alginate. Emdogain has
      been used for more than 16 years for regenerative periodontal treatment of intrabony, class
      II furcation and recession defects. Animal and human histological studies have provided
      evidence for periodontal regeneration (e.g. formation of root cementum, periodontal ligament
      and alveolar bone) following the application of Emdogain in conjunction with periodontal
      surgery. The use of Emdogain has been shown to significantly improve the clinical outcomes
      evidenced by probing depth reduction, and clinical attachment gain and is considered today as
      a routine procedure.

      Background Therapy of buccal gingival recession is a common indication for treatment in order
      to improve plaque control thus preventing gingivitis and root caries but also to improve
      aesthetics and root sensitivity. The ultimate goal of a root coverage procedure is the
      complete coverage of the root surface and, in the same time, to obtain a similar appearance
      of the regenerated soft tissues to the surrounding intact tissues. The use of palatal
      connective tissue graft in conjunction with a coronally advanced flap (CAF) is a well
      established clinical procedure for the treatment of gingival recessions. Its use has been
      shown to result in predictable root coverage, higher increase in keratinized tissue and more
      stable long-term outcomes compared to the use of CAF and is considered today state of the
      art. Furthermore, recent data also appear to indicate that the combination of Emdogain and
      CTG may additionally improve the clinical outcomes. Therefore, the standard surgical
      procedure for the treatment of gingival recessions at the Department of Periodontology
      includes the use of connective tissue graft either with or without the use of Emdogain.

      Interestingly, despite the fact that Emdogain is commonly used, no information on its effects
      upon early wound healing is available.

      Hence, the aim of this study is to evaluate the effect of Emdogain on early wound healing, as
      assessed by means of clinical parameters and inflammatory markers following recession
      coverage surgery.

      Study population and methodology Patient groups compared: in the treatment group, patients
      undergoing a recession coverage surgery will be treated with Emdogain whereas in the control
      group, patients will not receive Emdogain. A total of 40 patients, 20 in each group will be
      included.

      Preoperative inflammatory markers will be assessed at the preoperative examination and two
      days after surgery by dipping paper points into the crevicular fluid. Furthermore the
      investigators will assess whether remnants of Emdogain are still traceable two days after
      surgery. Wound healing after root coverage procedure is assessed using the "early wound
      healing index (EHI)" defined by Wachtel et al. According to Wachtel et al., wound healing is
      quantified and graded into 5 stages.

      Additionally, the post-operative healing process will be judged by a patient questionnaire.
      Finally root coverage is measured as the distance from the CEJ (Cemento Enamel Junction) to
      the Margo Gingivae in mm.

      Objective

        1. To investigate the benefit of intraoperative use of Emdogain on early wound healing
           during the first two weeks after gingival recession coverage. Early wound healing
           parameters will be assessed at both the site of explantation of the tissue graft as well
           as at the site of implantation.

        2. To investigate the effect of Emdogain on inflammatory markers in crevicular fluid and
           whether Emdogain is traceable after two days after application.

        3. To investigate its influence on post-operative pain and interference with daily
           activities during the first two weeks (patient's questionnaire).

        4. The post-operative result will also be assessed after 6 months.

      Methods

      The present prospective study will include a total of 40 patients, 20 patients in each of the
      2 groups (Emdogain group and control group). All procedures will be elective procedures.
      After oral and written informed consent, the study will comprise the collection of crevicular
      fluid sampling and clinical data as well as the filling of a patient questionnaire. The study
      will be conducted as randomized prospective study. In the treatment group the procedure will
      be performed with Emdogain, in the control group, root coverage will be performed without,
      respectively. All procedures will be performed by one experienced operator. Patients will all
      be treated with the standard surgical procedure of the University of Bern. In the patient
      group with Emdogain, tissue graft and explantation site will be covered with Emdogain, in the
      patient group without Emdogain, no Emdogain will be used. After inclusion of the patients,
      the study duration will last 6 months for each patient.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: Single (Outcomes Assessor)
measure: Change from baseline in wound healing
time frame: 2, 7 and 14 days after surgery
description: Progress in wound healing assessed by the "early wound healing index (EHI)" previously defined by Wachtel et al.
measure: Levels of post-procedural inflammatory markers
time frame: 2 and 7 days after surgery
description: Including IL- 8, IL-10, IL-1beta, MMP-8 and TGF beta-1, traceability of Emdogain in the operation field
measure: Improvement of patients' post-operative comfort
time frame: 2 days to 2 weeks after surgery
description: Assessed by patient questionnaire
measure: Root coverage
time frame: 6 months after surgery
description: Measured in mm
arm group label: Recession coverage without Emdogain
arm group type: Active Comparator
arm group label: Recession coverage with Emdogain
arm group type: Experimental
intervention type: Device
intervention name: Recession coverage without Emdogain
description: In the control group subjects the recession coverage surgery will be performed without Emdogain.
arm group label: Recession coverage without Emdogain
intervention type: Device
intervention name: Recession coverage with Emdogain
description: In the test group subjects the recession coverage surgery will be performed with Emdogain.
arm group label: Recession coverage with Emdogain
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Anton Sculean, Prof. Dr. med. dent.
role: Principal Investigator
affiliation: Department of Periodontology, University of Bern
facility: 
country: Switzerland
citation: Grandin HM, Gemperli AC, Dard M. Enamel matrix derivative: a review of cellular effects in vitro and a model of molecular arrangement and functioning. Tissue Eng Part B Rev. 2012 Jun;18(3):181-202. doi: 10.1089/ten.TEB.2011.0365. Epub 2011 Dec 28.
PMID: 22070552
citation: Spahr A, Haegewald S, Tsoulfidou F, Rompola E, Heijl L, Bernimoulin JP, Ring C, Sander S, Haller B. Coverage of Miller class I and II recession defects using enamel matrix proteins versus coronally advanced flap technique: a 2-year report. J Periodontol. 2005 Nov;76(11):1871-80. doi: 10.1902/jop.2005.76.11.1871.
PMID: 16274306
citation: Wachtel H, Schenk G, Bohm S, Weng D, Zuhr O, Hurzeler MB. Microsurgical access flap and enamel matrix derivative for the treatment of periodontal intrabony defects: a controlled clinical study. J Clin Periodontol. 2003 Jun;30(6):496-504. doi: 10.1034/j.1600-051x.2003.00013.x.
PMID: 12795787
citation: Cairo F, Pagliaro U, Nieri M. Treatment of gingival recession with coronally advanced flap procedures: a systematic review. J Clin Periodontol. 2008 Sep;35(8 Suppl):136-62. doi: 10.1111/j.1600-051X.2008.01267.x.
PMID: 18724847
citation: Henriques PS, Pelegrine AA, Nogueira AA, Borghi MM. Application of subepithelial connective tissue graft with or without enamel matrix derivative for root coverage: a split-mouth randomized study. J Oral Sci. 2010 Sep;52(3):463-71. doi: 10.2334/josnusd.52.463.
PMID: 20881341
citation: Cueva MA, Boltchi FE, Hallmon WW, Nunn ME, Rivera-Hidalgo F, Rees T. A comparative study of coronally advanced flaps with and without the addition of enamel matrix derivative in the treatment of marginal tissue recession. J Periodontol. 2004 Jul;75(7):949-56. doi: 10.1902/jop.2004.75.7.949.
PMID: 15341352
citation: Aroca S, Molnar B, Windisch P, Gera I, Salvi GE, Nikolidakis D, Sculean A. Treatment of multiple adjacent Miller class I and II gingival recessions with a Modified Coronally Advanced Tunnel (MCAT) technique and a collagen matrix or palatal connective tissue graft: a randomized, controlled clinical trial. J Clin Periodontol. 2013 Jul;40(7):713-20. doi: 10.1111/jcpe.12112. Epub 2013 Apr 30.
PMID: 23627374
citation: Rasperini G, Roccuzzo M, Francetti L, Acunzo R, Consonni D, Silvestri M. Subepithelial connective tissue graft for treatment of gingival recessions with and without enamel matrix derivative: a multicenter, randomized controlled clinical trial. Int J Periodontics Restorative Dent. 2011 Apr;31(2):133-9.
PMID: 21491012
responsible party type: Sponsor
mesh term: Gingival Recession